NDAORALTABLET
Approved
Apr 1996
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ESTROVIS (quinestrol) is an oral estrogen tablet approved in 1996 for hormone replacement therapy and related estrogen-deficiency indications. The mechanism of action involves estrogen receptor agonism to address menopausal and post-menopausal symptoms. Quinestrol is a synthetic estrogen with a long half-life, enabling less frequent dosing than some alternatives.
LOE Approaching
Approaching loss of exclusivity signals declining revenue trajectory; commercial teams should prepare transition strategies and may see reduced headcount or resource reallocation.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
ESTROVIS offers limited career expansion opportunities given its approaching loss of exclusivity and mature lifecycle stage. Roles focus on defending market share, managing generic transition, and optimizing profitability rather than growth-oriented activities.
Brand ManagerField Sales Representative
Worked on ESTROVIS at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.